TacticScaleWhat Organon Does & How It Makes Money (OGN)
Updated October 2026 · reflects Organon's latest reported financials
Women's health pharma with biosimilars and established brand-name medicines. It earns revenue by selling branded prescription drugs, biosimilars and devices to wholesalers, retailers, hospitals, clinics, governments, HMOs and pharmacy benefit managers across global markets.
How Organon makes money
It earns revenue by selling branded prescription drugs, biosimilars and devices to wholesalers, retailers, hospitals, clinics, governments, HMOs and pharmacy benefit managers across global markets.
What Organon does
Organon & Co. is a global healthcare company headquartered in Jersey City, New Jersey, with roots going back to 1923. Its core focus is women's health, anchored by contraceptives like the Nexplanon implant and NuvaRing, fertility treatments such as Follistim AQ, Elonva and Ganirelix, and newer products like Jada for postpartum bleeding and Xaciato for bacterial vaginosis. Beyond women's health, Organon has a growing biosimilars business in immunology (Renflexis, Hadlima, Brenzys), oncology (Ontruzant, Aybintio) and bone-related antibodies (Bildyos, Bilprevda). It also sells a broad set of established brands, including Zetia, Vytorin and Zocor for cholesterol, Cozaar and Hyzaar for hypertension, Singulair and Nasonex for respiratory and allergy conditions, Vtama for dermatology, Fosamax for bone health, and Proscar and Propecia. It sells worldwide through wholesalers, pharmacies, hospitals, governments and benefit managers.
Products & services
- Nexplanon
- NuvaRing
- Follistim AQ
- Hadlima
- Zetia/Vytorin
- Singulair
What is Organon worth?
On an owner-earnings DCF, Organon's most-likely value is about $21 versus a recent price near $14 (51% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$17) with a margin of safety — so the honest verdict here is “Deeply discounted.” Fair value earns its keep only at the extremes, not in the wide middle.
On the financials alone, $14 is below even the no-growth floor ($17); the market's discount — expectations and sentiment beyond the numbers — is pricing in ≈ -2.4%/yr. A bargain only if that pessimism is overdone.
⚠ High leverage — net debt is 17.1× annual cash flow. Net debt is subtracted from this fair value, but refinancing at higher rates, principal timing, and share dilution aren’t modeled — the equity can be worth far less if cash flow weakens.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Amgen (AMGN) · Porton Pharma Solutions (300363.SZ) · Livzon Pharmaceutical (000513.SZ)